Ferring Bravelle in vitro use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ferring's Bravelle (urofollitropin) is approved for use in in vitro fertilization Dec. 19. The human-derived follicle-stimulating hormone was shown to similar efficacy to genetically engineered FSH in two trials of patients undergoing controlled ovarian hyperstimulation for IVF. The studies found comparable pregnancy outcomes for Bravelle and Follistim (recombinant follitropin beta), with significantly less injection site pain, Ferring said. Bravelle was approved May 6, 2002, for ovulation induction following pituitary suppression (Pharmaceutical Approvals Monthly, June 1, 2002, In Brief). Ferring is also touting Bravelle as the lowest priced product in its categor
Ferring's Bravelle (urofollitropin) is approved for use in in vitro fertilization Dec. 19. The human-derived follicle-stimulating hormone was shown to similar efficacy to genetically engineered FSH in two trials of patients undergoing controlled ovarian hyperstimulation for IVF. The studies found comparable pregnancy outcomes for Bravelle and Follistim (recombinant follitropin beta), with significantly less injection site pain, Ferring said. Bravelle was approved May 6, 2002, for ovulation induction following pituitary suppression (Pharmaceutical Approvals Monthly, June 1, 2002, In Brief). Ferring is also touting Bravelle as the lowest priced product in its category |